Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
7(50%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_2
4
29%
Ph phase_3
2
14%
Ph phase_4
6
43%
Ph not_applicable
2
14%

Phase Distribution

0

Early Stage

4

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
6(42.9%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

14

all time

Status Distribution
Active(10)
Completed(4)

Detailed Status

Recruiting5
Completed4
Not yet recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (28.6%)
Phase 32 (14.3%)
Phase 46 (42.9%)
N/A2 (14.3%)

Trials by Status

active_not_recruiting214%
completed429%
not_yet_recruiting321%
recruiting536%

Recent Activity

7 active trials
Showing 5 of 14
recruitingphase_4

Vericiguat and Reverse Remodeling Indices in Heart Failure

NCT07405944
completedphase_2

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

NCT05711719
completedphase_3

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

NCT05093933
active_not_recruitingphase_4

Impact of Vericiguat on Hemodynamics of Heart Failure

NCT05704478
completedphase_4

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

NCT05420012
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07405944Phase 4

Vericiguat and Reverse Remodeling Indices in Heart Failure

Recruiting
NCT05711719Phase 2

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

Completed
NCT05093933Phase 3

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

Completed
NCT05704478Phase 4

Impact of Vericiguat on Hemodynamics of Heart Failure

Active Not Recruiting
NCT05420012Phase 4

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

Completed
NCT06239974Not Applicable

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Recruiting
NCT06601465Phase 2

COgnitioN With VERiciGuat Evaluation in Heart Failure

Recruiting
NCT05806138Phase 2

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

Active Not Recruiting
NCT07047547Not Applicable

A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure

Recruiting
NCT05812755Phase 4

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

Recruiting
NCT06415227Phase 2

The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris

Not Yet Recruiting
NCT06812546Phase 4

Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Not Yet Recruiting
NCT06671990Phase 4

The CardioMEMS Vericiguat Heart Failure Trial

Not Yet Recruiting
NCT02861534Phase 3

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14